论文部分内容阅读
目的:观察胺碘酮治疗充血性心力衰竭并室性心律失常的临床疗效和安全性。方法:采用随机、对照方法,将88例充血性心力衰竭并室性心律失常的患者分为治疗组(在常规治疗的基础上加胺碘酮治疗)和对照组(常规抗心力衰竭治疗)。治疗4周后,观察两组患者的左室射血分数、心力衰竭再住院率、药物不良反应。结果:治疗后两组间抗室性心律失常及心功能改善治疗组效果优于对照组,且再入院率低,与对照组比较有显著性差异(P<0.05),两组的不良反应无差异性(P>0.05)。结论:胺碘酮治疗充血性心力衰竭合并室性心律失常有效,且安全可靠。
Objective: To observe the clinical efficacy and safety of amiodarone in the treatment of congestive heart failure and ventricular arrhythmia. Methods: Eighty-eight patients with congestive heart failure and ventricular arrhythmia were divided into treatment group (treated with amiodarone on the basis of routine treatment) and control group (treated in conventional anti-heart failure) by randomized and controlled method. After 4 weeks of treatment, left ventricular ejection fraction, heart failure rehospitalization rate and adverse drug reactions were observed in both groups. Results: After treatment, anti-ventricular arrhythmia and improvement of cardiac function were better in the treatment group than in the control group, and the rate of re-admission was lower than that in the control group (P <0.05). There was no adverse reaction in the two groups Difference (P> 0.05). Conclusion: Amiodarone is effective and safe in treating congestive heart failure with ventricular arrhythmia.